JP2018536621A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536621A5 JP2018536621A5 JP2018511684A JP2018511684A JP2018536621A5 JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5 JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018511684 A JP2018511684 A JP 2018511684A JP 2018536621 A5 JP2018536621 A5 JP 2018536621A5
- Authority
- JP
- Japan
- Prior art keywords
- independently
- xaa
- cancer
- macrocycle
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562214142P | 2015-09-03 | 2015-09-03 | |
| US62/214,142 | 2015-09-03 | ||
| US201662310254P | 2016-03-18 | 2016-03-18 | |
| US62/310,254 | 2016-03-18 | ||
| US201662344651P | 2016-06-02 | 2016-06-02 | |
| US201662344791P | 2016-06-02 | 2016-06-02 | |
| US62/344,791 | 2016-06-02 | ||
| US62/344,651 | 2016-06-02 | ||
| PCT/US2016/050194 WO2017040990A1 (en) | 2015-09-03 | 2016-09-02 | Peptidomimetic macrocycles and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536621A JP2018536621A (ja) | 2018-12-13 |
| JP2018536621A5 true JP2018536621A5 (enExample) | 2019-10-17 |
| JP6971970B2 JP6971970B2 (ja) | 2021-11-24 |
Family
ID=58188595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018511684A Expired - Fee Related JP6971970B2 (ja) | 2015-09-03 | 2016-09-02 | ペプチド模倣大環状分子およびその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20170114098A1 (enExample) |
| EP (1) | EP3344275B8 (enExample) |
| JP (1) | JP6971970B2 (enExample) |
| KR (1) | KR20180043835A (enExample) |
| CN (1) | CN108348571B (enExample) |
| AU (1) | AU2016315878A1 (enExample) |
| BR (1) | BR112018003985A2 (enExample) |
| CA (1) | CA2996685A1 (enExample) |
| IL (1) | IL257706A (enExample) |
| MX (1) | MX2018002723A (enExample) |
| WO (1) | WO2017040990A1 (enExample) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0720306A2 (pt) | 2006-12-14 | 2014-02-04 | Aileron Therapeutics Inc | Sistemas de macrociclização da bis-sufidrila |
| PL2118123T3 (pl) | 2007-01-31 | 2016-06-30 | Dana Farber Cancer Inst Inc | Stabilizowane peptydy p53 i ich zastosowania |
| CA2678941C (en) | 2007-02-23 | 2018-11-27 | Aileron Therapeutics, Inc. | Triazole macrocycle systems |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| AU2010204648B2 (en) | 2009-01-14 | 2016-09-01 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| JP2013505300A (ja) | 2009-09-22 | 2013-02-14 | エルロン・セラピューティクス・インコーポレイテッド | ペプチド模倣大環状分子 |
| KR102104762B1 (ko) | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| EP2768518A4 (en) | 2011-10-18 | 2015-05-27 | Aileron Therapeutics Inc | PEPTIDOMIMETIC MACROCYCLES |
| RU2642299C2 (ru) | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
| BR112015009470A2 (pt) | 2012-11-01 | 2019-12-17 | Aileron Therapeutics Inc | aminoácidos dissubstituídos e seus métodos de preparação e uso |
| WO2014138429A2 (en) | 2013-03-06 | 2014-09-12 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and use thereof in regulating hif1alpha |
| CN107106642B (zh) | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| EP3197478A4 (en) | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2018516844A (ja) | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
| US10059741B2 (en) | 2015-07-01 | 2018-08-28 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles |
| EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| EP3527226A4 (en) * | 2016-10-17 | 2020-06-17 | Daiichi Sankyo Company, Limited | COMBINATION THERAPY PROCEDURE WITH MDM2 INHIBITOR AND DNA METHYL TRANSFERASE INHIBITOR |
| AU2017348322B8 (en) | 2016-10-28 | 2021-12-23 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating EZH2-mediated cancer |
| AU2017370694A1 (en) | 2016-12-08 | 2019-07-25 | Icahn School Of Medicine At Mount Sinai | Compositions and methods for treating CDK4/6-mediated cancer |
| CN110291089B (zh) | 2017-01-17 | 2022-05-27 | 海帕瑞吉尼克斯股份有限公司 | 用于促进肝再生或者减少或预防肝细胞死亡的蛋白激酶抑制剂 |
| CN110891588A (zh) * | 2017-05-11 | 2020-03-17 | 艾瑞朗医疗公司 | 拟肽大环化合物及其用途 |
| JP7780857B2 (ja) * | 2017-06-01 | 2025-12-05 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｐｄ－１抗体を用いる腫瘍の治療方法 |
| WO2018218633A1 (en) * | 2017-06-02 | 2018-12-06 | Beijing Percans Oncology Co. Ltd. | Combination therapies for treating cancers |
| WO2019173516A1 (en) | 2018-03-06 | 2019-09-12 | Icahn School Of Medicine At Mount Sinai | Serine threonine kinase (akt) degradation / disruption compounds and methods of use |
| WO2019195959A1 (en) | 2018-04-08 | 2019-10-17 | Cothera Biosciences, Inc. | Combination therapy for cancers with braf mutation |
| CA3104298A1 (en) | 2018-06-21 | 2019-12-26 | Icahn School Of Medicine At Mount Sinai | Wd40 repeat domain protein 5 (wdr5) degradation / disruption compounds and methods of use |
| WO2020023502A1 (en) * | 2018-07-23 | 2020-01-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP7507145B2 (ja) | 2018-08-13 | 2024-06-27 | ベイジン パーカンズ オンコロジー カンパニー リミテッド | 癌治療のためのバイオマーカー |
| CN120795059A (zh) | 2018-08-27 | 2025-10-17 | 瑞泽恩制药公司 | 拉曼光谱在下游纯化中的应用 |
| WO2020112868A1 (en) * | 2018-11-30 | 2020-06-04 | Aileron Therapeutics, Inc. | Combination therapy of peptidomimetic macrocycles |
| US20220040166A1 (en) * | 2018-12-11 | 2022-02-10 | Kartos Therapeutics | Methods and Compositions of Treating an Ophthalmic Condition |
| CN109731104A (zh) * | 2018-12-29 | 2019-05-10 | 苏州明基医院有限公司 | 一种多肽-稀土材料递送系统及制备方法和应用 |
| EP3938051A4 (en) * | 2019-03-15 | 2022-12-07 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AND USES THEREOF |
| WO2020198734A1 (en) * | 2019-03-28 | 2020-10-01 | The Penn State Research Foundation | Methods, compositions relating to treatment of cancer |
| US12465648B2 (en) | 2019-05-06 | 2025-11-11 | Icahn School Of Medicine At Mount Sinai | Heterobifunctional compounds as degraders of HPK1 |
| WO2021202961A1 (en) * | 2020-04-02 | 2021-10-07 | United States As Represented By Dept Of Veterans Affairs | Methods of treating immunotherapy resistant metastatic melanoma |
| US12103924B2 (en) | 2020-06-01 | 2024-10-01 | Icahn School Of Medicine At Mount Sinai | Mitogen-activated protein kinase kinase (MEK) degradation compounds and methods of use |
| WO2021262484A1 (en) | 2020-06-24 | 2021-12-30 | Pmv Pharmaceuticals, Inc. | Combination therapy for treatment of cancer |
| CN111825621A (zh) * | 2020-07-22 | 2020-10-27 | 天津理工大学 | 一种奥拉帕尼与丙二酸的共晶及其制备方法 |
| US11760747B2 (en) | 2020-12-21 | 2023-09-19 | Alkermes, Inc. | Substituted piperidino compounds and related methods of treatment |
| CN115137731B (zh) * | 2022-05-19 | 2023-11-21 | 上海交通大学医学院附属新华医院 | Flt3抑制剂及其药学上可接受的盐在制备治疗皮肤t细胞淋巴瘤药物中的应用 |
| WO2024083223A1 (zh) * | 2022-10-21 | 2024-04-25 | 正大天晴药业集团股份有限公司 | 大环类化合物及其医药用途 |
| GB202219576D0 (en) * | 2022-12-22 | 2023-02-08 | Univ Court Univ Of Glasgow | Polypeptides |
| IL326910A (en) * | 2023-10-20 | 2026-05-01 | Alkermes Inc | Compound for use in the treatment of narcolepsy |
| WO2025096608A1 (en) * | 2023-10-31 | 2025-05-08 | The Board Of Trustees Of The Leland Stanford Junior University | Egfr covalent inhibition with macrocycles |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5364851A (en) | 1991-06-14 | 1994-11-15 | International Synthecon, Llc | Conformationally restricted biologically active peptides, methods for their production and uses thereof |
| US5446128A (en) | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| US5824483A (en) | 1994-05-18 | 1998-10-20 | Pence Inc. | Conformationally-restricted combinatiorial library composition and method |
| US5811515A (en) | 1995-06-12 | 1998-09-22 | California Institute Of Technology | Synthesis of conformationally restricted amino acids, peptides, and peptidomimetics by catalytic ring closing metathesis |
| US6713280B1 (en) | 1999-04-07 | 2004-03-30 | Thomas Jefferson University | Enhancement of peptide cellular uptake |
| US7192713B1 (en) | 1999-05-18 | 2007-03-20 | President And Fellows Of Harvard College | Stabilized compounds having secondary structure motifs |
| WO2004056875A1 (en) | 2002-12-23 | 2004-07-08 | Wyeth | Antibodies against pd-1 and uses therefor |
| US7202332B2 (en) | 2004-05-27 | 2007-04-10 | New York University | Methods for preparing internally constrained peptides and peptidomimetics |
| PL2161336T5 (pl) | 2005-05-09 | 2017-10-31 | Ono Pharmaceutical Co | Ludzkie przeciwciała monoklonalne przeciwko białku Programmed Death 1 (PD-1) oraz sposoby leczenia raka z zastosowaniem samych przeciwciał anty-PD-1 lub w połączeniu z innymi środkami immunoterapeutycznymi |
| CA2612241C (en) | 2005-07-01 | 2018-11-06 | Medarex, Inc. | Human monoclonal antibodies to programmed death ligand 1 (pd-l1) |
| US7932397B2 (en) | 2006-11-22 | 2011-04-26 | Massachusetts Institute Of Technology | Olefin metathesis catalysts and related methods |
| JP5631201B2 (ja) | 2007-03-28 | 2014-11-26 | プレジデント アンド フェローズ オブ ハーバード カレッジ | ステッチングされたポリペプチド |
| KR101586617B1 (ko) | 2007-06-18 | 2016-01-20 | 머크 샤프 앤 도메 비.브이. | 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체 |
| BRPI0906685A2 (pt) | 2008-01-25 | 2016-10-11 | Massachusetts Inst Technology | catalisadores para reações de metátese incluindo metátese de olefina enantiosseletiva, e métodos relacionados |
| JP2012500652A (ja) | 2008-08-25 | 2012-01-12 | アンプリミューン、インコーポレーテッド | 標的化共刺激ポリペプチドおよび癌を処置するための使用方法 |
| CA2743177A1 (en) * | 2008-11-24 | 2010-05-27 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles with improved properties |
| EP4209510B1 (en) | 2008-12-09 | 2024-01-31 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
| WO2011097642A1 (en) | 2010-02-08 | 2011-08-11 | Trustees Of Boston College | Efficient methods for z- or cis-selective cross-metathesis |
| KR102104762B1 (ko) * | 2010-08-13 | 2020-04-24 | 에일러론 테라퓨틱스 인코포레이티드 | 펩티도미메틱 거대고리 |
| EP2739358B1 (en) | 2011-08-01 | 2018-11-28 | F.Hoffmann-La Roche Ag | Methods of treating cancer using pd-1 axis binding antagonists and mek inhibitors |
| RU2642299C2 (ru) | 2012-02-15 | 2018-01-24 | Эйлерон Терапьютикс, Инк. | P53 пептидомиметические макроциклы |
| US20150011728A1 (en) * | 2012-02-22 | 2015-01-08 | New York University | Reversibly crosslinked helical hydrogen bond surrogate macrocycles |
| RS60142B1 (sr) * | 2013-12-05 | 2020-05-29 | Hoffmann La Roche | Novi kombinovani tretman za akutnu mijeloidnu leukemiju (aml) |
| CN107106642B (zh) * | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
| EP3197478A4 (en) * | 2014-09-24 | 2018-05-30 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
| JP2018516844A (ja) * | 2015-03-20 | 2018-06-28 | エルロン・セラピューティクス・インコーポレイテッドＡｉｌｅｒｏｎ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | ペプチド模倣大環状分子およびその使用 |
-
2016
- 2016-09-02 CA CA2996685A patent/CA2996685A1/en active Pending
- 2016-09-02 CN CN201680064031.0A patent/CN108348571B/zh not_active Expired - Fee Related
- 2016-09-02 KR KR1020187009277A patent/KR20180043835A/ko not_active Ceased
- 2016-09-02 AU AU2016315878A patent/AU2016315878A1/en not_active Abandoned
- 2016-09-02 EP EP16843105.4A patent/EP3344275B8/en active Active
- 2016-09-02 US US15/256,130 patent/US20170114098A1/en not_active Abandoned
- 2016-09-02 MX MX2018002723A patent/MX2018002723A/es unknown
- 2016-09-02 JP JP2018511684A patent/JP6971970B2/ja not_active Expired - Fee Related
- 2016-09-02 BR BR112018003985A patent/BR112018003985A2/pt not_active Application Discontinuation
- 2016-09-02 WO PCT/US2016/050194 patent/WO2017040990A1/en not_active Ceased
-
2018
- 2018-02-25 IL IL257706A patent/IL257706A/en unknown
-
2020
- 2020-05-22 US US16/881,564 patent/US20200369728A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6971970B2 (ja) | ペプチド模倣大環状分子およびその使用 | |
| CN109414470A (zh) | 用于拟肽大环化合物的伴随诊断工具 | |
| US11091522B2 (en) | Peptidomimetic macrocycles and uses thereof | |
| JP2018516844A (ja) | ペプチド模倣大環状分子およびその使用 | |
| CN106999541A (zh) | 拟肽大环化合物及其用途 | |
| JP2020519595A (ja) | ペプチド模倣大環状分子およびその使用 | |
| AU2018202672A1 (en) | Peptidomimetic macrocycles | |
| CN114173878A (zh) | 拟肽大环化合物及其用途 | |
| WO2020112868A1 (en) | Combination therapy of peptidomimetic macrocycles | |
| HK40043424A (en) | Peptidomimetic macrocycles and uses thereof |